



LEI: 549300Q7EXQQH6KF7Z84

26 March 2025

**RTW Biotech Opportunities Ltd**  
(the "Company")

**Transaction in Own Shares**

The Company announces that on 25 March 2025 it bought back 200,000 of its Ordinary Shares at a price of £1.255 per Ordinary Share.

The repurchased Ordinary Shares will be held by the Company in treasury. Following the purchase and settlement of these Ordinary Shares, the Company's issued Ordinary Share capital is 345,967,440 of which 11,103,791 Ordinary Shares will be held in treasury, which attract no voting rights. Therefore, the total voting rights in the Company will be 334,863,649.

The Company has bought back these Ordinary Shares under the authority granted by shareholders at its Annual General Meeting in May 2024, which permits the Company to repurchase a maximum of 14.99% of its Ordinary Shares. The actual number of Ordinary Shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2025), or until expressly revoked by shareholders.

The above figure of 334,863,649 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any Ordinary Shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company's current intention to hold any Ordinary Shares bought back in treasury.

The Company has instructed Deutsche Numis as its broker in respect of its buyback transactions. This arrangement is in accordance with the FCA Listing Rules and the Company's general authority to repurchase shares.

**Enquiries:**

<b>RTW Investments, LP - Investment Manager</b>	+44 (0)20 7959 6361
Woody Stileman (Business Development)	biotechopportunities@rtwfunds.com
Oliver Kenyon (Business & Corporate Development)	
Krishna McCune (Investor Relations)	

<b>Deutsche Numis - Joint Corporate Broker</b>	+44 (0)20 7260 1000
Freddie Barnfield	
Nathan Brown	
Euan Brown	

**About RTW Biotech Opportunities Ltd:**

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at [www.rtwfunds.com/rtw-biotech-opportunities-ltd](http://www.rtwfunds.com/rtw-biotech-opportunities-ltd) for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSUVONRVNUOUAR